Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia
Background. Acute myeloblastic leukemia (AML) with NPM1 mutation amounts to 30 % of all AML and is characterized by good prognosis with the exception of cases with FLT3-ITD mutation. Despite the good prognosis, the likelihood of relapses in patients with NPM1 mutation may significantly differ. Thus,...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2017-10-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2017/10/8_1.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305450223239168 |
|---|---|
| author | LL Girshova IG Budaeva EG Ovsyannikova SO Kuzin DV Motorin RSh Badaev DB Zammoeva VV Ivanov KV Bogdanov OS Pisotskaya YuV Mirolyubova TS Nikulina YuA Alekseeva AYu Zaritskii |
| author_facet | LL Girshova IG Budaeva EG Ovsyannikova SO Kuzin DV Motorin RSh Badaev DB Zammoeva VV Ivanov KV Bogdanov OS Pisotskaya YuV Mirolyubova TS Nikulina YuA Alekseeva AYu Zaritskii |
| author_sort | LL Girshova |
| collection | DOAJ |
| description | Background. Acute myeloblastic leukemia (AML) with NPM1 mutation amounts to 30 % of all AML and is characterized by good prognosis with the exception of cases with FLT3-ITD mutation. Despite the good prognosis, the likelihood of relapses in patients with NPM1 mutation may significantly differ. Thus, the estimation of the minimal residual disease (MRD) after chemotherapy and during follow-up is becoming increasingly important. This approach will make it possible to predict the sensitivity of a tumoral clone to chemotherapy.
Aim. To evaluate the prognostic value of highly specific marker (NPM1 mutation) and non-specific marker (WT1 overexpression) of MRD, as well as to identify the correlation between the levels of NPM1 and WT1 at different stages of therapy and in the follow-up period.
Materials & Methods. The research included 14 patients with AML. All patients had the NPM1 mutation and WT1 overexpression: 50 % of patients had additional molecular markers (BAALC overexpression, FLT3-ITD, DNMT3A, and MLL mutations). Real-time PCR was used for long-term monitoring of WT1 expression levels and NPM1 mutation.
Results. The median decrease of NPM1 levels after the induction therapy was 3 log. All patients had relapses, NPM1 mutation, and lower rates of OS/RFS, which significantly correlated with prognostically negative molecular markers. There were no statistically significant differences in RFS in groups with the decrease of WT1 expression level < 2 log and > 2 log on day 28 of treatment. At the same time, the decrease of WT1 expression by > 2 log was associated with significant differences in early relapses, which correlated with the decrease of NPM1 levels (> and < than 3 log) is revealed. RFS rates were higher in patients with WT1 expression level of < 100 per 104 copies ABL on day 28 and WT1 of < 250 per 104 copies ABL on day 14 of treatment. WT1 expression was significantly lower on days 14 and 28 in patients with NPM1 decrease of > 3 log on day 28. The decrease in WT1 expression of < 100 per 104 copies ABL on day 28 was more common in patients with isolated NPM1 mutation, compared to patients with additional negative molecular markers.
Conclusion. The decrease in NPM1 levels after the induction therapy may serve as reliable prognostic marker of RFS and OS rates. New correlation between the degree of NPM1 reduction and the presence of additional molecular markers was established. Highly specific (NPM1 mutation) was shown to be more specific compared to non-specific markers (WT1 overexpression). The research showed the predictive value of a lower limit level of WT1 on day 28 of treatment (100 per 104 copies ABL), and for the first time, the importance of the early assessment WT1 expression reduction on day 14 of induction therapy. |
| format | Article |
| id | doaj-art-09f6fdb173664535b657d9eb1587cdf0 |
| institution | Kabale University |
| issn | 1997-6933 2500-2139 |
| language | Russian |
| publishDate | 2017-10-01 |
| publisher | Practical Medicine Publishing House |
| record_format | Article |
| series | Клиническая онкогематология |
| spelling | doaj-art-09f6fdb173664535b657d9eb1587cdf02025-08-20T03:55:27ZrusPractical Medicine Publishing HouseКлиническая онкогематология1997-69332500-21392017-10-0110448549310.21320/2500-2139-2017-10-4-485-493Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic LeukemiaLL Girshova0IG Budaeva1EG Ovsyannikova2SO Kuzin3DV Motorin4RSh Badaev5DB Zammoeva6VV Ivanov7KV Bogdanov8OS Pisotskaya9YuV Mirolyubova10TS NikulinaYuA Alekseeva11AYu Zaritskii12VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341VA Almazov National Medical Research Center, 2 Akkuratova str., Saint Petersburg, Russian Federation, 197341Background. Acute myeloblastic leukemia (AML) with NPM1 mutation amounts to 30 % of all AML and is characterized by good prognosis with the exception of cases with FLT3-ITD mutation. Despite the good prognosis, the likelihood of relapses in patients with NPM1 mutation may significantly differ. Thus, the estimation of the minimal residual disease (MRD) after chemotherapy and during follow-up is becoming increasingly important. This approach will make it possible to predict the sensitivity of a tumoral clone to chemotherapy. Aim. To evaluate the prognostic value of highly specific marker (NPM1 mutation) and non-specific marker (WT1 overexpression) of MRD, as well as to identify the correlation between the levels of NPM1 and WT1 at different stages of therapy and in the follow-up period. Materials & Methods. The research included 14 patients with AML. All patients had the NPM1 mutation and WT1 overexpression: 50 % of patients had additional molecular markers (BAALC overexpression, FLT3-ITD, DNMT3A, and MLL mutations). Real-time PCR was used for long-term monitoring of WT1 expression levels and NPM1 mutation. Results. The median decrease of NPM1 levels after the induction therapy was 3 log. All patients had relapses, NPM1 mutation, and lower rates of OS/RFS, which significantly correlated with prognostically negative molecular markers. There were no statistically significant differences in RFS in groups with the decrease of WT1 expression level < 2 log and > 2 log on day 28 of treatment. At the same time, the decrease of WT1 expression by > 2 log was associated with significant differences in early relapses, which correlated with the decrease of NPM1 levels (> and < than 3 log) is revealed. RFS rates were higher in patients with WT1 expression level of < 100 per 104 copies ABL on day 28 and WT1 of < 250 per 104 copies ABL on day 14 of treatment. WT1 expression was significantly lower on days 14 and 28 in patients with NPM1 decrease of > 3 log on day 28. The decrease in WT1 expression of < 100 per 104 copies ABL on day 28 was more common in patients with isolated NPM1 mutation, compared to patients with additional negative molecular markers. Conclusion. The decrease in NPM1 levels after the induction therapy may serve as reliable prognostic marker of RFS and OS rates. New correlation between the degree of NPM1 reduction and the presence of additional molecular markers was established. Highly specific (NPM1 mutation) was shown to be more specific compared to non-specific markers (WT1 overexpression). The research showed the predictive value of a lower limit level of WT1 on day 28 of treatment (100 per 104 copies ABL), and for the first time, the importance of the early assessment WT1 expression reduction on day 14 of induction therapy.http://bloodjournal.ru/wp-content/uploads/2017/10/8_1.pdfacute myeloblastic leukemiaAMLNPM1WT1molecular monitoring |
| spellingShingle | LL Girshova IG Budaeva EG Ovsyannikova SO Kuzin DV Motorin RSh Badaev DB Zammoeva VV Ivanov KV Bogdanov OS Pisotskaya YuV Mirolyubova TS Nikulina YuA Alekseeva AYu Zaritskii Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia Клиническая онкогематология acute myeloblastic leukemia AML NPM1 WT1 molecular monitoring |
| title | Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia |
| title_full | Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia |
| title_fullStr | Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia |
| title_full_unstemmed | Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia |
| title_short | Prognostic Value and Correlation Between WT1 Overexpression and NPM1 Mutation in Patients with Acute Myeloblastic Leukemia |
| title_sort | prognostic value and correlation between wt1 overexpression and npm1 mutation in patients with acute myeloblastic leukemia |
| topic | acute myeloblastic leukemia AML NPM1 WT1 molecular monitoring |
| url | http://bloodjournal.ru/wp-content/uploads/2017/10/8_1.pdf |
| work_keys_str_mv | AT llgirshova prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT igbudaeva prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT egovsyannikova prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT sokuzin prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT dvmotorin prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT rshbadaev prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT dbzammoeva prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT vvivanov prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT kvbogdanov prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT ospisotskaya prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT yuvmirolyubova prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT tsnikulina prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT yuaalekseeva prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia AT ayuzaritskii prognosticvalueandcorrelationbetweenwt1overexpressionandnpm1mutationinpatientswithacutemyeloblasticleukemia |